2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Do-Youn Oh, MD, PhD, discusses the results of the phase 3 TOPAZ-1 trial in advanced biliary tract cancer.
Do-Youn Oh, MD, PhD, professor, Division of Medical Oncology, Department of Internal Medicine, Seoul National University Hospital and Seoul National University College of Medicine, Seoul, South Korea, discusses the results of the phase 3 TOPAZ-1 trial (NCT03875235) in advanced biliary tract cancer (BTC).
During the 2022 Gastrointestinal Cancers Symposium, the results of the TOPAZ-1 trial were presented. The findings demonstrated a significantly improved overall survival with durvalumab (Imfinzi) in combination with gemcitabine/cisplatin vs placebo plus chemotherapy when used as frontline therapy in patients with advanced BTC. Moreover, the immunotherapy-containing regimen led to a 20% reduction in the risk of death compared with the placebo-containing regimen, Oh says.
Moreover, other end points, such as progression-free survival and objective response rate were improved with durvalumab/chemotherapy vs placebo/chemotherapy in this patient population, Oh explains.
Regarding safety, the frequency of adverse effects was similar between arms, suggesting that most toxicities were related to the chemotherapeutic agents, Oh concludes.